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Summary
High-throughput sequencing of the DNA/RNA encoding antibody heavy-
and light-chains is rapidly transforming the field of adaptive immunity. It
can address key questions, including: (i) how the B-cell repertoire differs
in health and disease; and (ii) if it does differ, the point(s) in B-cell devel-
opment at which this occurs. The advent of technologies, such as whole-
genome sequencing, offers the chance to link abnormalities in the B-cell
antibody repertoire to specific genomic variants and polymorphisms.
Here, we discuss the current research using B-cell antibody repertoire
sequencing in three polygenic autoimmune diseases where there is good
evidence for a pathological role for B-cells, namely systemic lupus erythe-
matosus, multiple sclerosis and rheumatoid arthritis. These autoimmune
diseases exhibit significantly skewed B-cell receptor repertoires compared
with healthy controls. Interestingly, some common repertoire defects are
shared between diseases, such as elevated IGHV4-34 gene usage. B-cell
clones have effectively been characterized and tracked between different
tissues and blood in autoimmune disease. It has been hypothesized that
these differences may signify differences in B-cell tolerance; however, the
mechanisms and implications of these defects are not clear.
Keywords: antibodies; autoantibodies; autoimmunity; B-cell; B-cell
receptors.
Introduction
B-cells produce antibodies and are crucial for effective
immunity. B-cell clones selectively expand following antigen
recognition by B-cell receptors (BCRs). BCRs are the mem-
brane-form of antibodies and are generated through DNA
recombination. B-cells have the potential to recognize a
vast array of pathogens, but diversity in the B-cell reper-
toire comes at a price, namely that there is a potential for
autoreactivity in a subset of B-cells. Defects in B-cell devel-
opment and function can lead to a breakdown of immuno-
logical tolerance and therefore autoimmune diseases, which
affect approximately 1 in 12 people worldwide.1
B-cells develop from haematopoietic stem cells and dif-
ferentiate through several maturation stages in the bone
marrow. The germline immunoglobulin heavy-chain
(IgH) gene locus encodes multiple distinct copies of the
variable (V), diversity (D) and joining (J) genes, which
are separated by over 100 kbp from a much smaller num-
ber of DNA segments encoding the constant genes.2 Dur-
ing B-cell development, functional immunoglobulin genes
are generated through the deletion of intervening DNA,3
creating a IgH gene containing one V, one D and one J
gene (VDJ). This encodes the protein sequence for the
antigen-binding region of the IgH protein2,4 (Fig. 1). This
process of site-specific recombination is highly orches-
trated and mediated by recombination activating genes 1
(RAG1) and 2 (RAG2).5,6 The imprecise joining of the V,
D and J gene segments leads to the introduction of ran-
dom deletions and insertions of nucleotides through
exonucleases and terminal deoxynucleotidyl transferase
(TdT), respectively. This results in sequence diversifica-
tion at the junctional regions.7 Further mechanisms that
contribute to the generation of diversity include alterna-
tive IgHD reading frames and IgHD–IgHD fusions.8
These pre-B-cells are selected for functional heavy-chain
by IgV-D-J expression and IgH assembly by pairing.9,10
Likewise, each IgL chain locus encodes multiple distinct
copies of k chain and j chain variable (V) gene segments
and joining (J) gene segments.11 When a cell has success-
fully rearranged a IgH gene, the B-cell begins to rearrange
the light-chain genes. Therefore, each mature antigen-
na€ıve B-cell typically expresses BCR sequences encoding
the heavy- and light-chains. After functional V-(D)-J
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Figure 1. Schematic diagram of the processes of B-cell differentiation and selection, annotated with known human genetic modifiers of the pro-
cess and the point in selection at which they are thought to act. B-cells are generated from haematopoietic stem cells. During B-cell development,
V-D-J recombination occurs to produce a functional heavy-chain. Similarly, V-J recombination occurs in the light-chain. The resulting B-cell
receptor (BCR) may be expressed as both surface IgD and IgM on na€ıve B-cells through alternative splicing. Somatic hypermutation (SHM) can
occur during B-cell activation, in which mutations are introduced into the V-(D)-J region of the BCR. Class-switch recombination (CSR) can
also occur during B-cell activation, which is a chromosomal deletion process leading to the expression of a different antibody isotype.
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recombination of IgH and IgL chain genes, the resulting
immature na€ıve B-cells transcribe the IgH and IgL genes,
and are able to produce IgD and IgM immunoglobulin
isotype by alternative splicing of the transcript to fuse the
l and d exon to the IgHJ exon, respectively.12 At this
immature B-cell stage, the cells are first tested for toler-
ance to self-antigens.
Central tolerance
Immature B-cells that have no reactivity for self-antigen
leave the bone marrow. For self-reactive B-cells, there are
four possible fates.
(1) Deletion – this predominates when the self-antigen is
multivalent.
(2) Receptor editing – the continued expression of RAG
means that the light-chain of any self-reactive B-cell
can be deleted and replaced with another sequence.
Receptor editing is particularly amenable to analysis
by BCR sequencing (Box 1).
(3) Anergy – a state of unresponsiveness that occurs
when B-cells encounter weakly cross-linking self-anti-
gens of low valence.
(4) Ignorance – the B-cell does not encounter the self-
antigen for which it is specific in the bone marrow.
It might yet do so in the periphery.
Some autoreactive B-cells escape central tolerance. In
humans, approximately 55%–75% of the early immature
B-cells in humans are autoreactive. This decreases to 40%
for bone marrow immature B-cells and transitional B-
cells, and to approximately 20% for mature na€ıve B-
cells.13,14 Autoreactive B-cells therefore remain present in
the peripheral repertoire, and autoantibodies can be
found in healthy humans and mice (reviewed in15).
Therefore, within a human B-cell population, there will
be a continuum of autoreactivity.
Diversification of the repertoire in the periphery and
peripheral tolerance
Through B-cell activation through antigen binding by the
BCR in addition to auxiliary signals, BCR genes can be fur-
ther diversified through somatic hypermutation (SHM) in
the germinal centre16 (Box 2) and/or undergo class-switch
recombination (CSR; Box 3). In some species, gene con-
version can also take place. All three processes are depen-
dent on the activation-induced deaminase (AID) enzyme.
SHM diversifies the variable region by introducing point
mutations and this leads to affinity maturation. Clearly,
the process of SHM also has the potential to drive the for-
mation of newly autoreactive B-cells in the periphery. For
autoreactive cells that escape central tolerance, peripheral
tolerance mechanisms can prevent overt autoreactivity.
These include: (i) deletion of autoreactive B-cell clones in
the periphery; (ii) the functional suppression of B-cells
through anergy; and (iii) immunomodulation through reg-
ulatory T-cell and B-cell subsets; and (iv) a lack of T-cell
help from a cognate autoreactive T-cell.
Some individuals will generate and retain a greater
number of autoreactive clones or clones with higher affin-
ity for particular self-antigens arising at any of these
Box 1 Receptor editing
If a maturing na€ıve B-cell has high affinity for self-antigens or
does not form a functional BCR, the cells may be removed by
developmental arrest and/or induced programmed cell death in
the bone marrow. These B-cells can be rescued by modifying the
V-J light-chain recombination so that the B-cell receptor no
longer recognizes self-antigens or creates a new functional read-
ing frame.52,116 This occurs by the process of secondary rear-
rangement, where renewed IgHV-D-J or light-chain rearrange
ment can result in expression of a functional and non-autoreac-
tive BCR. Receptor editing is again mediated by RAG1/2.117–119
An upstream V gene recombines with the original V-D-J rear-
rangement to generate a BCR with a new BCR specificity. This
occurs between a cryptic recombination signal sequence within
the original rearrangement leaving behind a ~5 nucleotide foot-
print from the original V gene within the secondary rearranged
BCR.120 As IgHD-J recombinations (including junctional
regions), known as ‘stem sequences’ are stable in instances of sec-
ondary rearrangements,121 these can be identified in BCR reper-
toire sequencing. However, exonucleases and TdT may introduce
random deletions and insertions at this new junctional region,
which may obscure the V replacement footprint.122 Although this
can confound inference of secondary rearrangements events from
BCR sequencing, secondary rearrangements result in longer
CDR3 regions, which is a feature that can be tracked using BCR
repertoire sequencing data.
Box 2 Somatic hypermutation (SHM)
SHM is a process that introduces point mutations and, occasion-
ally, insertions and deletions into the variable regions of the
heavy-chain immunoglobulin, where some of the resulting popu-
lations are expanded through positive selection for higher affinity
antigen binding.123 These lead to some B-cells improving their
antigen specificity and affinity to the antigen, often by several
orders of magnitude.124,125 This process is mediated through the
action of cell type-specific expression activation-induced cytosine
deaminase enzyme (AID). SHM can be determined from BCR
sequencing data on comparison with reference germline genes.
However, SHM needs to be distinguished from germline alleles
present in an individual that are not recorded in a reference
database. Germline genes may be inferred from sequencing data
(through programmes such as IMPre126), against which SHM
may be determined.
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stages of diversification. Such individuals may be at
higher risk of developing an autoimmune disease.
B-cell receptor sequencing is helping us address key
questions in the field of B-cell repertoire development, and
how B-cell populations differ between health and disease.
B-cells play important roles in a range of autoimmune dis-
eases. Here, we discuss the current research on B-cell reper-
toire in the most well-studied of these polygenic
autoimmune diseases with evidence for the role of B-cells
in pathology, namely systemic lupus erythematosus (SLE),
multiple sclerosis (MS) and rheumatoid arthritis (RA).
SLE
Systemic lupus erythematosus is an autoimmune disease
that is characterized by immune complex deposition with
concomitant inflammation in almost any organ. Renal
involvement, in the form of glomerulonephritis, occurs in
about 40% of cases and is associated with a higher mor-
tality. Over 100 autoantibody targets are associated with
SLE, and antinuclear antibodies are present in more than
95% of patients. Autoantibodies can be present years
before the onset of clinical symptoms.17 Transfer of
human autoantibodies from patients with SLE can cause
glomerulonephritis and proteinuria in murine experimen-
tal systems,18,19 emphasizing that they can be pathogenic.
Genome-wide association studies (GWAS) have shown
that over 80 loci can contribute to the risk of developing
SLE.20 The pathogenesis of the disease is complex, but
several broad themes emerge. Multiple genes involved in:
(i) the clearance of immune complexes and apoptotic
cells; (ii) the regulation of innate immunity, such as the
type 1 interferon and complement pathways; and (iii) the
regulation of lymphocyte activation and function have
been implicated.
The pathogenicity of autoantibodies and the large
number of GWAS risk loci that are involved in B-cell
development and function suggest B-cells are a key
driver of disease.21,22 A central question, then, is how
the B-cell repertoire is altered in SLE and whether this
can be related to specific polygenic or monogenic dri-
vers of disease. Here we discuss the current studies
performed on B-cell repertoire in SLE (summarized in
Table 1).
B-cell population differences in SLE
Patients with SLE exhibit significantly different B-cell sub-
population frequencies in peripheral blood. These may be
a cause or consequence of autoimmunity, but they should
be considered when discussing how the BCR repertoire
differs from healthy controls. The abnormalities include
the following.
• Significantly decreased numbers of na€ıve B-cells.23
• More self-reactive B-cells than healthy individuals.24,25
• Increased frequencies of double-negative (CD27-class-
switched) B-cells,26–28 which has been shown to corre-
late with increased autoantibody titres.26
• Increased levels of CD19lowCD27high plasma cells,23
which may be a consequence of systemic inflamma-
tion.29
Germline repertoire variation in the Ig locus in SLE
One reason for studying the BCR repertoire is that varia-
tion in germline immunoglobulin heavy-chain (IGHV)
genes has been associated with disease susceptibility.
Homozygous deletions of IGHV3-30*01 and IGHV3-30-3
were found to be enriched 28-fold in SLE patients with
nephritis compared with ethnically matched healthy indi-
viduals, and SLE patients with these deletions exhibited
higher titres of anti-DNA antibodies.30,31 This deletion
has also been shown to be associated with susceptibility
to chronic idiopathic thrombocytopaenic purpura32 and
Kawasaki disease33 (reviewed in Watson et al.34).
Peripheral B-cell repertoire analysis in SLE
Analysis of peripheral blood B-cells using BCR sequencing
can provide important information in four key areas,
summarized in Table 1. These are as follows.
• Variable gene usage.
• Clonality and CDR3 length.
• SHM.
• CSR.
Variable gene usages in SLE
B-cell receptor sequencing of antibody repertoires in
patients with SLE have shown significant changes in
Box 3 Class-switch recombination (CSR)
There are five major classes of antibody isotype, namely IgM,
IgD, IgG1/2/3/4, IgA1/2 and IgE, each with distinct functions
through engagement of different activating or inhibitory Fc
receptors, and leading to the activation of different immune cells.
Through varying the isotype, an antibody can exhibit significant
differences in antigen avidity, through dimerization or polymer-
ization of IgA1 and IgM, respectively,127,128 as well as binding
distinct sets of antibody (Fc) receptors, and ultimately inducing
distinct immune responses.129 B-cell activation can lead to iso-
type class-switching from IgM to IgG, IgA, IgD or IgE through
recombination and deletion processes, known as CSR. This pro-
cess is coordinated by activation-induced cytosine deaminase
enzyme (AID) and occurs primarily within the germinal centre
through close cooperation between B-cells and T-helper cells via
the interaction of B-cell surface CD40 protein and CD40L, which
is expressed by activated T-helper cells.130
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IGHV gene usages compared with healthy individuals.
This has been observed in multiple studies, suggesting
differences in B-cell selection and antigen-specific B-cell
clonal expansion. All the BCR sequencing studies to date
have shown an enrichment of IGHV4 gene family
usages,17,23,35,36 specifically IGHV4-34.17,36 IGHV4-34 was
the dominant serum autoantibody IGHV gene.17 Notably,
IGHV4-34 is strongly associated with autoreactivity, with
unmutated IgHV4-34 genes containing the AVY motifs in
the framework region 1 known to recognize I/i self-anti-
gen against red blood cell antigens.37,38 IGHVH4-34 gene-
containing antibodies have also been shown to recognize
other autoantigens and include anti-DNA antibodies,39–42
rheumatoid factors (antibodies against the Fc portion of
IgG),43 as well as commensal bacteria44. Some other
IGHV families have also been found to be enriched in
peripheral blood B-cells SLE, including IGHV1 and
IGHV3.35,45 These data are therefore consistent with the
idea that the peripheral B-cell repertoire may be skewed
towards autoreactivity in patients with SLE.
Clonality and CDR3 region composition of antibodies in
SLE
High-throughput sequencing of BCR repertoires from
peripheral blood has shown that patients with SLE exhibit
increased B-cell clonality compared with heathy individu-
als.46,47 This is characterized by polyclonal (multiple) B-
cell expansions.36 This is possibly secondary to increased
numbers of plasmablasts. In a patient with active SLE, it
is likely that plasmablasts generated by the ongoing
immune response will be more numerous in peripheral
blood. As these plasmablasts have higher levels of BCR
RNA per cell, the apparent clonality of the peripheral B-
cell population may increase when sequencing BCR reper-
toires are sourced from B-cell RNA.
The complementarity determining region 3 (CDR3) is
the most variable region of the antibody sequence
(Fig. 1). Longer CDR3 lengths have been associated with
both auto- and polyreactivity.48 Interestingly, patients
with SLE display significantly shorter CDR3 lengths in B-
cells from peripheral blood46 than controls. Again though,
this might be due to increased proportions of plas-
mablasts in peripheral blood in SLE as na€ıve B-cell BCRs
tend to have longer CDR3 lengths than antigen-experi-
enced B-cells.49 Some of the difficulties interpreting such
data could be resolved through isotype-specific BCR
sequencing or through investigation of cell-sorted B-cell
populations, including na€ıve, memory and plasma cells.
As well as changes in CDR3 length, patients with SLE also
appear to have qualitative differences in the CDR3 region
compared with controls. For instance, CDR3s from B-
cells from patients with SLE code for significantly higher
proportions of charged amino acids, such as arginine, but
the functional significance of such changes is unclear.
SHM in SLE
There are numerous reports suggesting that patients with
SLE exhibit increased levels of SHM compared with
healthy controls. This provides potential mechanistic
insight into the pathogenesis of SLE. If SHM is not strin-
gently controlled and/or B-cells in the germinal centre
receive inappropriate help from autoreactive T-cells, then
autoimmunity might ensue. Accordingly, Dorner and col-
leagues described increased levels of SHM in SLE from
CD19 + B-cells23,50,51 as well as CD27hi plasma cells.23
These authors also showed that the peripheral memory
BCR repertoire in SLE is shaped by abnormal selection,
increased SHM and increased receptor editing.52 In agree-
ment with this, Sfikakis et al.53 showed increased levels of
SHM in SLE.
Isotype in SLE
Certain isotypes are associated with autoreactivity, and
potentially pathogenicity, in SLE. IgG anti-dsDNA anti-
bodies have been found to be more closely associated
with SLE disease activity and tissue damage than IgM
antibodies.54 Indeed, some studies suggest that IgM anti-
DNA antibodies may be protective,55 whereas other iso-
types may also play a role in disease.56–58 However, there
are no systematic BCR sequencing studies in SLE that
incorporate analysis of isotypes. Isotype-resolved BCR
repertoire sequencing on peripheral blood or tissue B-
cells subpopulations may be able to provide clues to the
extent to which a particular clone has undergone CSR
and the relative contributions of each isotype to a certain
autoantibody specificity.
B-cell repertoire during or after therapy in SLE
Systemic lupus erythematosus is currently treated with
anti-malarial drugs such as hydroxychloroquine. Some
patients are escalated to anti-proliferative medication such
as azathioprine, methotrexate or mycophenolate mofetil
in more severe disease. Corticosteroids are frequently
used during flares to gain control of disease activity. B-
cell depletion therapies with, for example, rituximab
(anti-CD20) can be used in refractory disease. There is
wide variation in the treatment regime used in patients
with SLE, and limited data on how the repertoire changes
with therapy. An interesting and unresolved question is
whether any particular features of the repertoire correlate
with either sustained clinical remission or treatment resis-
tance. It is known that certain B-cell subsets such as anti-
gen-experienced CD27 + IgD-class-switched memory B-
cells are not well targeted by therapy and that this may
contribute to treatment resistance. A study of the BCR
repertoires of two patients with SLE before and after
high-dose glucocorticoid therapy showed that IGHV3
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gene family usage decreased after treatment,59 but CDR3
region composition was similar at all time points. While
the titre of some anti-nuclear antibodies reduced after
treatment, they did not find evidence of a reduction in
clone sizes over this time. In a study of patients with
active SLE given rituximab, clonally related B-cells were
found to be persistent in all seven patients, but not found
in any of the four age-matched healthy controls.53 This
is consistent with preferential depletion of na€ıve and
CD20high B-cells, with the surviving B-cell population
consisting of CD20low B-cells, including plasmablasts60
and mucosal IgA + plasmablasts that are not removed
by B-cell depletion therapy. As yet, however, there has
been no large-scale analysis of BCR usage in a large num-
ber of patients on ‘standard-of-care’ non-B-cell depleting
therapy.
Conclusions in SLE
These studies have shown that the B-cell repertoire dif-
fers between healthy controls and patients in SLE. How-
ever, it is still unclear how these relate to disease
pathology, either as a cause or consequence of chronic
inflammation. It is possible that both defects in central
and peripheral tolerance in inadequate removal of
autoreactive B-cells in SLE and, to some extent, these
could be dissected through the study of monogenic dri-
vers of autoimmunity.
A good example of this is a paper by Menard et al.
They used BCR sequencing and ELISA of recombinant
antibodies to study the R620W polymorphism in PTPN22
that is implicated in susceptibility to autoimmune disease.
They showed that B-cells from carriers of this PTPN22
risk allele contained high frequencies of autoreactive
clones compared with those from non-carriers showing
how a single polymorphism at one genetic locus can
affect the B-cell repertoire.61 This PTPN22 polymorphism
is a gain-of-function variant leading to reduced B- and
T-cell receptor signalling,62,63 and has been associated
with a range of autoimmune diseases, including RA,64,65
type 1 diabetes66 and SLE.67 Similar studies on variation
in other genes are likely to provide further useful infor-
mation on how specific biological pathways regulate the
B-cell repertoire.
Unanswered BCR repertoire questions remaining in
SLE include the following.
• What are the differences in B-cell repertoire in SLE
patients on an isotype level and the differences between
peripheral blood and affected tissues?
• How do specific genetic loci affect the B-cell reper-
toire?
• How does the repertoire change with disease course
and with therapy?
• Can we use BCR sequencing to predict disease progno-
sis or outcome?
MS
Multiple sclerosis is an autoimmune disorder characterized
by inflammation in the central nervous system (CNS).68 It
is the most common chronic neurological disorder in
young Caucasian adults.69 MS initially presents as transient
inflammation leading to demyelination of neurons, and is
characterized initially by relapsing and remitting episodes
of neurological dysfunction. Remyelination with functional
recovery may occur between episodes in early disease. Over
time, however, the pathology is dominated by extensive
microglial activation and neurodegeneration. Functionally
this leads to progressive disability.68 As with any autoim-
mune disease, the pathogenesis of MS is driven by a com-
bination of genetic susceptibility and environmental
factors.70–72 The presence of B-cell clonal expansions and
oligoclonal immunoglobulin bands (i.e. an increased con-
centration of a restricted number of antibodies) in the
cerebrospinal fluid (CSF) of the majority of patients sug-
gests a role for B-cells in MS pathology.69 Intrathecal
plasma cells, B-cells, antibody and complement activation
have all been observed in MS,73 and intrathecal antibody
production was noted in very early studies of the disease.74
The positive effects of B-cell depletion therapies and the
observation that IGHV2 gene polymorphisms have been
associated with susceptibility to MS75,76 indicate that B-
cells and antibodies play a significant role in MS. Many
autoantigens have been proposed as pathogenic antibody
targets in MS, including those derived from the following.
• Myelin-derived antigens [such as myelin oligodendro-
cyte glycoprotein (MOG), myelin basic protein
(MBP),77 proteolipid protein and myelin-associated
glycoprotein].
• Oligodendrocytes (such as CNPase, transaldolase and
transketolase).
• Axons (such as neurofilament light-chain, tubulin and
neurofascin).
• Astrocytes (such as potassium channel KIR4.1).
• Ubiquitous autoantigens (such as heat-shock proteins
and nuclear proteins).
• Microbial antigens.77,78
Given the evidence that B-cells contribute to de-myelina-
tion, there have been numerous studies of the B-cell reper-
toire in MS, typically focussing on B-cells in CSF and blood
(summarised in Table 2). A particularly exciting aspect of
repertoire analysis in MS is the ability to compare the
repertoire of B-cells that have infiltrated the CNS with
those in the peripheral blood. This may give vital clues to
disease pathogenesis and how the immune response at the
site of inflammation differs from the systemic response.
B-cell repertoire analysis in MS
As before, however, the studies can be divided into those
providing insight into variation in the following.
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• Variable gene usage.
• Clonal expansion.
• SHM.
• CSR.
Variable gene usage in MS
The presence of oligoclonal immunoglobulin bands in the
majority of patients with MS suggests that B-cell clonal
expansion is a feature of the disease,69,79,80 specifically as
IgG and IgM.81 However, there is no definitive evidence
that these B-cells target myelin or other CNS compo-
nents. Through both spectrotyping and high-throughput
sequencing, increased usage of IGHV1 and IGHV4 fami-
lies,69,82–84 specifically IGHV1-69, IGHV4-34 and IGHV4-
39, have all been found in the brains of patients with
MS.82 Overrepresentation of IGHD2, IGHD3 and IGHJ4
families has also been described.82 More recent studies
using high-throughput sequencing have shown B-cells in
the CSF of patients with MS are not representative of
peripheral blood lymphocytes, indicating tissue-specific
clonal B-cell expansion and localization.85
The composition of the BCR repertoire was found to be
distinct between peripheral blood and CSF, with markedly
different frequencies of IGHV, D and J usages.79 Com-
pared with the periphery, the IGHV4 family was found to
be overrepresented in the CNS of matched CSF samples,
suggestive of enrichment of antigen-specific B-cells into
this region. The difference between peripheral and CSF
compartments may alternatively be due to differences in
B-cell subpopulations: the majority of B-cells in MS
patients in CSF have memory or short-lived plasmablast
phenotypes,86 which have been shown to have a distinct
IGHV gene usage profile to that of na€ıve B-cells, which
comprise the majority of peripheral blood B-cells.87
Clonal expansion, SHM and CSR in MS
B-cell receptor sequencing has shown that CSF-infiltrating
B-cells exhibit evidence of somatic mutation69,79,80,84,85,88
and CSR.79,80,83,84 Indeed, ectopic lymphoid tissues have
been found in the meninges of patients with MS and
these exhibit germinal centre activity, and both IgM and
class-switched B-cells have been found in the CSF. Beltran
and colleagues found that IgM+ B-cells from CSF showed
high degrees of SHM, whereas IgM+ B-cells from periph-
eral blood were primarily unmutated because they were
na€ıve B-cells.84
Somatic hypermutation analysis may also be used to
estimate the evolutionary relationship between B-cells of
different phenotypes or from different anatomical loca-
tions. This allows direct inference of clonal tracking
between peripheral blood and CSF. Indeed, clonally
related B-cells have been identified spanning both the
peripheral blood and CSF in several studies derived from
post-germinal centre B-cells, as evidenced by extensive
levels of SHM.80,83 These studies are suggestive of bi-
directional exchange of B-cells across the blood–brain
barrier. Interestingly, founding members of B-cell clones,
defined as B-cells expressing BCRs most closely resem-
bling germline, were more often found in draining cervi-
cal lymph nodes (CLNs), whereas more mature clone
members, defined as B-cells expressing hypermutated
BCRs, were observed in both draining CLNs and the CNS
itself.79 However, there is still controversy about where
SHM and class-switching occurs in MS. For instance,
Stern et al. suggest that the majority of B-cell maturation
occurs outside the CNS in secondary lymphoid tissue.79
By contrast, Palanichamy et al. suggest that SHM may
occur in both the CNS tertiary lymphoid structures and
in the CLN.83 Indeed, a third study has shown that B-cell
lineages with members in both the CNS and CLN are
prone to undergo additional rounds of affinity matura-
tion,86 further suggesting ongoing and complex B-cell
dynamics between sites of affinity maturation, circulation
and lesions.86 The differences in conclusions from these
studies are likely to result from differences in sampling
sites and depth. There is also likely to be significant varia-
tion between patients, including variation in their disease
course or treatment.
B-cell repertoire during or after therapy in MS
There are few studies on the effect of treatment on
antibody repertoire in MS. A study of three patients
with CNS demyelination after a single dose of ritux-
imab corresponded with significant loss of peripheral
B-cells, including IgG memory B-cells.89 Within the IgG
memory B-cell population, there was no significant
change in IGHV, D or J gene usage, CDR3 region
length or charge before and after therapy. However, the
frequencies of clonally expanded IgG memory B-cells
significantly increased after therapy, corresponding to
preferential depletion of na€ıve and CD20high B-cells,
with the remainder low-level B-cell population consist-
ing of CD20low B-cells, including plasmablasts.60 How-
ever, further studies are required to determine the
differences between therapies and if there are B-cell
repertoire features associated with remission and long-
term outcome.
Conclusions in MS
Whilst BCR sequencing has highlighted the potential clo-
nal relationships between blood and brain in MS, it is still
unknown how and where such B-cells differentiate and
their contribution to pathogenesis. The emergence of
high-throughput screening technologies alongside BCR
sequencing may help elucidate the antigenic targets of
CSF-infiltrating B-cells. However, determining whether
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B-cell infiltration is a result of reactivity against a com-
mon self-antigen or a result of infection or bystander
activation is, as yet, unclear. Unanswered BCR repertoire
questions remaining in MS are as follows.
• What are the differences in B-cell repertoire in MS
between CSF and other (non-peripheral blood) tissue
sites? A key question is the exact location where
autoreactive clones arise and proliferate in MS.
• Can BCR sequencing be used to delineate whether there
are differences in central and peripheral B-cell selection
in MS patients compared with healthy individuals?
RA
Rheumatoid arthritis is one of the most common chronic
inflammatory disorders mainly targeting synovial
membrane of diarthrodial joints, but other systemic man-
ifestations may also present in patients.90 Again, the effi-
cacy of B-cell depletion therapies, such as anti-CD20,91
have pointed to a key role for B-cells. Alterations in B-cell
tolerance have been posited to play a role in RA. In par-
ticular, BCR editing,92 clonal deletion and anergy have
been shown to be defective.93
The pathological nature of autoantibodies in RA
remains controversial. Autoantibody production in
patients with RA is well described. Rheumatoid factor
and anti-citrullinated protein antibodies (ACPA)94,95 are
the most well studied. Infiltrating lymphocytes have been
identified in the majority of synovial tissue samples in
patients with RA.96,97 In about 10% of patients, these
manifest as large follicle-like structures, known as synovial
germinal centres.98,99 Furthermore, studies have shown
Table 3. BCR repertoire sequencing analyses in RA
References Sample number
Synovial B-cells
IGHV4 family
usage increased
Clonal
expansions
observed
Longer
CDR3
regions
B-cells
undergone
SHM
B-cells
undergone
CSR
(Voswinkel et al.
1997)103
3 RA patients Yes
(Pascual and
Capra 1992)104
Monoclonal
antibodies
from various
diseases
Yes: IGHV4–34
(Doorenspleet
et al. 2014)105
12 RA patients Yes: IGHV4–34 Yes. Peripheral
blood dominant
clones disappeared
during active disease
and appeared in
the synovial tissue
Yes Yes
(Samuels et al.
2005)92
9 RA patients Yes Yes
(Lee et al.
1992)106
1 RA patient NA: IGK2
light-chains
enriched
Yes Yes
(Tak et al.
2017)108
21 individuals
at risk for RA
Yes. Peripheral blood
dominant clones
disappeared during
active disease and
appeared in the
synovial tissue
(Kim et al.
1999)99
1 RA patient Yes Some SHM observed.
(Morbach et al.
2011)110
31 juvenile
idiopathic
arthritis patients
Yes, and CSR
(Amara et al.
2013)109
6 RA patients Yes
(Tan et al.
2014)94
16 RA patients Yes
CDR3, complementarity determining region 3; CSR, class-switch recombination; RA, rheumatoid arthritis; SHM somatic hypermutation.
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that the proportion of peripheral blood plasmablasts is
positively correlated with disease activity in RA,94,100 and
these have been found to produce ACPAs.94,95 In a man-
ner redolent of SLE and MS, IGHV gene polymorphisms
associate with susceptibility to RA, most notably in
IGHV1-69.101,102 Given the association of B-cells in RA
pathology, we review the current research in BCR reper-
toire sequencing in RA (summarized in Table 3). The
majority of studies in RA have focused on synovial tissue
and peripheral blood repertoires.
B-cell repertoire analysis in RA
Variable gene usages in RA
Multiple studies have shown enrichment of IGHV4 genes
in the BCR repertoires from synovial tissue from RA
patients, specifically IGHV4-34.103–106 This includes syn-
ovial plasma cells,103 which are antibody-secreting cells.
Studies of the light-chain BCR repertoire have also shown
enrichment of the kappa IGK2 gene family segments in RA
synovium B-cells,106 which have been associated with anti-
RF activity.107 In agreement with this, Samuels et al.92
showed evidence of different levels of receptor editing dur-
ing central tolerance through analysis of kappa light-chain
BCR repertoire. These data are consistent with, though not
diagnostic of, a breakdown of B-cell tolerance in RA.
BCR clonality and CDR3 lengths in RA
Several papers have shown evidence of B-cell clonal
expansions in the synovial tissue of patients with
RA.92,94,99,105,108 Indeed, in a prospective study of 21
individuals at risk of RA, the risk of developing RA dur-
ing follow-up was significantly associated with the pres-
ence of ≥ 5 dominant BCR clones, defined as clonally
related BCRs representing > 05% of the total reper-
toire.108 This was validated in an independent prospec-
tive cohort of 50 at-risk individuals. Interestingly, when
individuals developed RA, the clones seen in peripheral
blood were no longer detectable there but could be
found in synovial tissue, suggesting that activated B-cell
clones migrate to target tissue during active disease. This
is in agreement with a previous study showing that dur-
ing active RA, there were multiple dominant clones
within the inflamed synovial tissue that were absent
from peripheral blood.105 Furthermore, within individual
patients, the same dominant B-cell clones were observed
in different joints, suggesting that they migrated between
sites of inflammation.108 Together, this highlights that
B-cell expansions are present at the sites of inflamma-
tion in RA; however, the role and antigenic specificities
of these expanded clones is unknown.
Interestingly, expanded or dominant synovial B-cell
clones also showed features of autoreactivity. B-cell
clones from patients with RA were enriched for longer
CDR3 lengths in both the heavy-chain92,105,106 and light-
chain (kappa, Igj).92,106 B-cells with BCRs containing
long Igj CDR3 regions (of ≥ 11 amino acids) were
found to be autoreactive or polyreactive.92 Thus, a pic-
ture emerges in which B-cells from patients with RA
and particularly B-cells from inflamed joints appear
enriched for V gene usage that is associated with speci-
ficity for self-antigen.
SHM analysis in RA
There is mounting evidence for antigen-driven B-cell
affinity maturation and selection in patients with RA,
particularly within joints. Using single-cell sequencing
and monoclonal antibody expression of B-cells from the
joints of ACPA+ RA patients with active disease, 25% of
synovial IgG-expressing B-cells were specific for citrulli-
nated autoantigens; however, these were not found in
ACPA-negative RA patients.109 While some of the ACPAs
bound more than one citrullinated antigen, none was
reactive to non-citrullinated antigen. Furthermore, when
SHMs from ACPAs were reverted back to corresponding
germline sequences, anti-citrullinated peptide reactivity
was lost.
Despite evidence for SHM within synovial tissue
CD20 + B-cells in RA,99,105 the question of whether con-
tinued SHM occurs here has not been comprehensively
addressed in RA. In a related disease, juvenile idiopathic
arthritis, CD27 + IgD- and CD27 – IgD- B-cells accumu-
late in the joints of patients, and express somatically
hypermutated and class-switched BCRs.110 Indeed, these
cells displayed activated phenotypes, expressing co-stimu-
latory molecules CD80/CD86 and were able to activate
allogeneic T-cells more potently than their peripheral
blood B-cell counterparts, consistent with a role in
driving disease.
CSR in RA
Class-switched mature memory subsets were enriched in
the synovial compartment compared with peripheral
blood.111–113 Switching occurred primarily to IgG and
IgA.114 Evidence for class-switched autoreactive B-cells in
RA is also supported by other studies,105,109 where ~25%
of synovial IgG+ B-cells were reactive to citrullinated
autoantigens in ACPA-positive RA patients,109 and pro-
duction of ACPAs by RA peripheral blood IgG+ plas-
mablasts was found in ACPA+ RA patients, but not
ACPA RA or psoriatic arthritis patients.94 Tan et al.
examined B-cell specificities in RA using DNA barcoding
and sequencing of heavy- and light-chains of antibodies
expressed by plasmablasts. The antigen-specificities of
antibodies encoded by IgG+ plasmablasts from patients
with RA were tested using microarrays from
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recombinantly expressed antibodies.94 They showed that
representative antibodies from patients with RA were able
to bind cyclic citrullinated peptides from epitopes on a-
enolase, citrullinated fibrinogen and citrullinated histone
H2B in an ongoing B-cell response in RA. Furthermore,
these antibodies were not reactive to the non-citrullinated
form of these peptides, suggesting that the activated B-
cells that are present during active disease are selected for
their ability to bind citrullinated antigens. This demon-
strates that class-switched B-cells within the synovium are
both autoreactive, class-switched and somatically hyper-
mutated, suggesting a breakdown of peripheral tolerance.
However, the sites of SHM and CSR for autoreactive B-
cells are currently unknown.
B-cell repertoire during or after therapy in RA
There are only a small number of studies examining the
effect of therapy on the BCR repertoire in RA. Rouziere
et al.115 evaluated the effect of rituximab on B-cell reper-
toires in two patients with active RA, and showed that B-
cell depletion lasted between 5 and 7 months. B-cell
reconstitution was characterized by a diverse BCR reper-
toire and IGHV gene usages similar to that of healthy
adults. However, during the early phase of B-cell reconsti-
tution (5–7 months post-rituximab initiation) there was
an expansion and circulation of B-cells containing BCRs
with significantly higher levels of somatic mutations. This
corresponds to preferential depletion of na€ıve and
CD20high B-cells,60,111 and similar to the effects observed
in SLE53 and MS.89 Indeed, it was shown that IgG serum
concentrations were significantly reduced after a first
infusion of rituximab in a study of 35 patients with RA,
but IgA and IgM serum concentrations were stable until
3-12 months afterwards.111 Consistent with this, there was
a different IGHV gene usage distribution at this time
point, and the B-cell repertoire was enriched for class-
switched BCRs.115 Whilst this demonstrates significant
remodelling of the B-cell repertoire after B-cell depletion
therapy, the level of clonal persistence and association
with disease outcome has not yet been assessed.
Key outstanding questions in RA
Most studies to date have focused on synovium B-cell
population BCR repertoires, highlighting differences from
peripheral blood. It is unsurprising that there are signifi-
cant differences in BCR repertoire between these com-
partments. However, the most exciting results arise from
the presence of dominant clonal expansions in the
peripheral blood that precede clinical presentation and
therefore might be predictive of disease development.
This is especially pertinent as such clones migrate to the
synovium in active disease. The next steps will be to
determine the sites of autoreactive B-cell generation in
RA: whether these clonal expansions arise within synovial
germinal centres, or within other anatomic sites and
undergo migration to the synovium. Indeed, sampling of
different anatomic sites and B-cell clonal tracking through
the BCR in high-risk or early clinical RA patients may
shed more light on the early dynamics of autoreactive B-
cells.
Concluding remarks
B-cell receptor repertoire sequencing has, so far, been
used most effectively to characterize and track B-cell
clones between different tissues and blood. Such studies
suggest migration of B-cells between peripheral blood and
the CSF in MS, and between blood and synovium in RA.
Often, these autoreactive B-cells have also undergone
SHM and/or CSR, suggesting a role for the germinal cen-
tre in their generation. However, the exact location where
affinity maturation occurs is not always clear and is an
important question. Indeed, the presence of ectopic ger-
minal centres in synovial tissue or CSF in RA and MS,
respectively, still allows for the possibility that B-cell
clones matured in one site cannot then migrate to
another. In agreement with this, the circulation of mem-
bers of B-cell clones present in the inflamed tissues in MS
and RA demonstrates that these autoreactive B-cells are
able to undergo systematic immunosurveillance.
A second key finding across these diseases is the dis-
tinct patterns of variable gene usages and CDR3 lengths
between healthy individuals and patients with SLE, MS or
RA. It has been hypothesized that these differences may
signify differences in B-cell tolerance. However, different
B-cell subpopulations exhibit significantly different vari-
able gene usages and CDR3 lengths. Some of these dis-
ease-specific differences may therefore reflect changes in
the relative size of B-cell subpopulations.
The relative contributions of central and peripheral tol-
erance in developing autoreactive B-cell clones in these
diseases are currently unknown. Autoreactive B-cell clones
clearly arise from a breakdown in tolerance, though
whether this arises at the level for central or peripheral
tolerance is unknown. BCR repertoire sequencing of
sorted na€ıve and antigen-experienced B-cell populations
may provide some insight into central tolerance mecha-
nisms in different diseases. It has been argued that defec-
tive central tolerance would generate a na€ıve B-cell
population with a higher proportion of B-cells with
higher affinities to autoantigen. A difference in na€ıve B-
cell populations could be assessed by skewed V gene
usages and CDR3 lengths as well as assessment of affinity
for auto-antigen affinity ELISA. Dissecting the role of
peripheral tolerance may be more complex, particularly
when central tolerance may also be defective. Differences
in the levels and patterns of SHM and CSR have been
demonstrated most clearly between SLE and healthy
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individuals. However, whether this is a result of abnormal
na€ıve B-cell repertoire generation is not clear.
Much can be learnt about these processes from investi-
gations into Mendelian disorders of B-cell development.
Indeed, the study of the effect of monogenic drivers or
GWAS associations of autoimmune disease may help to
unravel the role of different stages of B-cell selection. This
was demonstrated by the defective counter-selection of
autoreactive B-cells in individuals with the PTPN22 gene
polymorphism. The advent of exome and whole-genome
sequencing of individuals with inherited disorders of B-
cell development and function is set to pave the way to
identify hitherto unknown coding and non-coding varia-
tion that influences the B-cell development (and thus
antibody) repertoire (Fig. 1).61 Indeed, with distinct
genetic signals from each autoimmune disease, we are
likely to observe distinct differences between different
autoimmune diseases.
As presented here, most of the studies to date on BCR
sequencing in autoimmune diseases are limited by small
numbers of patients. A meta-analysis of published data is
not possible due to the different BCR sequencing meth-
ods or sample sources used. The combined approaches of
isotype-specific BCR sequencing coupled with cell sorting
of specific B-cell subsets and other complementary tech-
nologies are likely to make great advances in the field.
Furthermore, (i) understanding the changes in B-cell
populations over disease course, (ii) associations with dis-
ease severity, and (iii) how this responds to different
immune-modulatory therapies will be critical to under-
stand how to improve patient outcomes. While the
advances that have been made in treating autoimmune
disease have been substantial, many patients experience
treatment-resistant disease despite the armoury of
immunosuppressants now available. Similarly, many cur-
rently used immunomodulatory drugs have pleiotropic
effects and an extensive side-effect profile. BCR sequenc-
ing in the context of autoimmune diseases is therefore
both timely and essential.
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